Kum Ju Chae, Hyunsook Hong, Hyungin Park, Soon Ho Yoon
{"title":"I期肺癌患者经胸肺活检缩短复发时间和无复发生存率的关系","authors":"Kum Ju Chae, Hyunsook Hong, Hyungin Park, Soon Ho Yoon","doi":"10.4143/crt.2024.560","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We aim to determine whether preoperative percutaneous needle aspiration or biopsy (PCNA/Bx) increases recurrence risk and reduces survival in stage I lung cancer patients, using a nationwide lung cancer registry.</p><p><strong>Materials and methods: </strong>We retrospectively included 3,452 patients diagnosed with stage I lung cancer who underwent curative surgery between 2014 and 2019, as recorded in the Korean Association of Lung Cancer Registry. To balance the characteristics of patients with and without PCNA/Bx, we applied inverse probability of treatment weighting. We used cumulative incidence plots and a weighted subdistribution hazard model to analyze time to recurrence. Recurrence-free survival and overall survival were analyzed using Kaplan-Meier curves and weighted Cox proportional hazard ratio models.</p><p><strong>Results: </strong>In patients with adenocarcinoma, the use of PCNA/Bx was associated with a 1.9-fold increase (95% CI, 1.5-2.4) in the risk of recurrence and a 1.7-fold decrease (95% CI, 1.3-2.2) in recurrence-free survival. Subgroup analysis based on pathologic pleural invasion revealed that the risk of recurrence increased when PCNA/Bx was performed, with 2.1-fold (95% CI, 1.5-2.8) in patients without pleural invasion and 1.6-fold (95% CI, 1.0-2.4) in those with pleural invasion. No association was found between the use of PCNA/Bx and overall survival.</p><p><strong>Conclusion: </strong>Preoperative PCNA/Bx was associated with increased recurrence risks in stage I adenocarcinoma, regardless of pathologic pleural invasion status. In early lung cancer cases where adenocarcinoma is strongly suspected and curative surgery is feasible, the use of transthoracic biopsy should be approached with caution.</p>","PeriodicalId":49094,"journal":{"name":"Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of Shorter Time to Recurrence and Recurrence-free Survival with Transthoracic Lung Biopsy in Stage I Lung Cancer.\",\"authors\":\"Kum Ju Chae, Hyunsook Hong, Hyungin Park, Soon Ho Yoon\",\"doi\":\"10.4143/crt.2024.560\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>We aim to determine whether preoperative percutaneous needle aspiration or biopsy (PCNA/Bx) increases recurrence risk and reduces survival in stage I lung cancer patients, using a nationwide lung cancer registry.</p><p><strong>Materials and methods: </strong>We retrospectively included 3,452 patients diagnosed with stage I lung cancer who underwent curative surgery between 2014 and 2019, as recorded in the Korean Association of Lung Cancer Registry. To balance the characteristics of patients with and without PCNA/Bx, we applied inverse probability of treatment weighting. We used cumulative incidence plots and a weighted subdistribution hazard model to analyze time to recurrence. Recurrence-free survival and overall survival were analyzed using Kaplan-Meier curves and weighted Cox proportional hazard ratio models.</p><p><strong>Results: </strong>In patients with adenocarcinoma, the use of PCNA/Bx was associated with a 1.9-fold increase (95% CI, 1.5-2.4) in the risk of recurrence and a 1.7-fold decrease (95% CI, 1.3-2.2) in recurrence-free survival. Subgroup analysis based on pathologic pleural invasion revealed that the risk of recurrence increased when PCNA/Bx was performed, with 2.1-fold (95% CI, 1.5-2.8) in patients without pleural invasion and 1.6-fold (95% CI, 1.0-2.4) in those with pleural invasion. No association was found between the use of PCNA/Bx and overall survival.</p><p><strong>Conclusion: </strong>Preoperative PCNA/Bx was associated with increased recurrence risks in stage I adenocarcinoma, regardless of pathologic pleural invasion status. In early lung cancer cases where adenocarcinoma is strongly suspected and curative surgery is feasible, the use of transthoracic biopsy should be approached with caution.</p>\",\"PeriodicalId\":49094,\"journal\":{\"name\":\"Cancer Research and Treatment\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4143/crt.2024.560\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4143/crt.2024.560","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:我们旨在利用全国范围内的肺癌登记资料,确定术前经皮穿刺针穿刺或活检(PCNA/Bx)是否会增加 I 期肺癌患者的复发风险并降低生存率:我们回顾性地纳入了韩国肺癌登记协会记录的2014年至2019年期间接受根治性手术的3452例I期肺癌患者。为了平衡有PCNA/Bx和无PCNA/Bx患者的特征,我们采用了逆治疗概率加权法。我们使用累积发病率图和加权子分布危险模型来分析复发时间。我们使用卡普兰-梅耶曲线和加权考克斯比例危险比模型分析了无复发生存率和总生存率:结果:在腺癌患者中,PCNA/Bx的使用与复发风险增加1.9倍(95% CI,1.5-2.4)和无复发生存率降低1.7倍(95% CI,1.3-2.2)有关。基于病理胸膜侵犯的亚组分析显示,进行PCNA/Bx检查时,复发风险增加,无胸膜侵犯的患者复发风险增加2.1倍(95% CI,1.5-2.8),有胸膜侵犯的患者复发风险增加1.6倍(95% CI,1.0-2.4)。PCNA/Bx的使用与总生存率之间没有关联:结论:无论病理胸膜侵犯状况如何,术前 PCNA/Bx 与 I 期腺癌复发风险增加有关。在强烈怀疑为腺癌且可行根治性手术的早期肺癌病例中,应谨慎使用经胸活检。
Association of Shorter Time to Recurrence and Recurrence-free Survival with Transthoracic Lung Biopsy in Stage I Lung Cancer.
Purpose: We aim to determine whether preoperative percutaneous needle aspiration or biopsy (PCNA/Bx) increases recurrence risk and reduces survival in stage I lung cancer patients, using a nationwide lung cancer registry.
Materials and methods: We retrospectively included 3,452 patients diagnosed with stage I lung cancer who underwent curative surgery between 2014 and 2019, as recorded in the Korean Association of Lung Cancer Registry. To balance the characteristics of patients with and without PCNA/Bx, we applied inverse probability of treatment weighting. We used cumulative incidence plots and a weighted subdistribution hazard model to analyze time to recurrence. Recurrence-free survival and overall survival were analyzed using Kaplan-Meier curves and weighted Cox proportional hazard ratio models.
Results: In patients with adenocarcinoma, the use of PCNA/Bx was associated with a 1.9-fold increase (95% CI, 1.5-2.4) in the risk of recurrence and a 1.7-fold decrease (95% CI, 1.3-2.2) in recurrence-free survival. Subgroup analysis based on pathologic pleural invasion revealed that the risk of recurrence increased when PCNA/Bx was performed, with 2.1-fold (95% CI, 1.5-2.8) in patients without pleural invasion and 1.6-fold (95% CI, 1.0-2.4) in those with pleural invasion. No association was found between the use of PCNA/Bx and overall survival.
Conclusion: Preoperative PCNA/Bx was associated with increased recurrence risks in stage I adenocarcinoma, regardless of pathologic pleural invasion status. In early lung cancer cases where adenocarcinoma is strongly suspected and curative surgery is feasible, the use of transthoracic biopsy should be approached with caution.
期刊介绍:
Cancer Research and Treatment is a peer-reviewed open access publication of the Korean Cancer Association. It is published quarterly, one volume per year. Abbreviated title is Cancer Res Treat. It accepts manuscripts relevant to experimental and clinical cancer research. Subjects include carcinogenesis, tumor biology, molecular oncology, cancer genetics, tumor immunology, epidemiology, predictive markers and cancer prevention, pathology, cancer diagnosis, screening and therapies including chemotherapy, surgery, radiation therapy, immunotherapy, gene therapy, multimodality treatment and palliative care.